Ĺ S S de Amorim

6PUBLICATIONS
17CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 13, 2024
APX2009 sensitizes hypoxic breast cancer cells to doxorubicin by increasing its accumulation and caspase-3/7-mediated apoptosis.

Ísis Salviano Soares de Amorim, Daphne Pinheiro, Matheus da Silva Oliveira

|May 29, 2024
The inhibitor of the redox activity of APE1/REF-1, APX2009, reduces the malignant phenotype of breast cancer cells.

P B Siqueira, M M S Rodrigues, Ĺ S S de Amorim

|Jan 02, 2024
The APE1/REF-1 and the hallmarks of cancer.

Priscyanne Barreto Siqueira, Mariana Moreno de Sousa Rodrigues, Ísis Salviano Soares de Amorim

|Feb 13, 2021
The tumor suppressor role of salvador family WW domain-containing protein 1 (SAV1): one of the key pieces of the tumor puzzle.

Ísis Salviano Soares de Amorim, Mariana Moreno de Sousa Rodrigues, Andre Luiz Mencalha

|Feb 06, 2021
5-Aza-2'-deoxycytidine induces a greater inflammatory change, at the molecular levels, in normoxic than hypoxic tumor microenvironment.

Ísis Salviano Soares de Amorim, Juliana Alves Rodrigues, Pedro Nicolau

|Apr 04, 2019
Regulation Is in the Air: The Relationship between Hypoxia and Epigenetics in Cancer.

Diego Camuzi, Ísis Salviano Soares de Amorim, Luis Felipe Ribeiro Pinto

Pageof 1

Frequent Collaborators

6 joint publications

André Luiz Mencalha

4 joint publications

Adenilson de Souza da Fonseca

3 joint publications

Juliana Alves Rodrigues

3 joint publications

Matheus da Silva Oliveira